Tie-Up Moves Kangstem's Novel Stem Cell Therapy Towards Globalization

 
• By Jung Won Shin

Helped by a new partnership with Belgium-based MaSTherCell, the South Korean biotech is aiming to initially challenge the European market with a stem cell therapy for atopic dermatitis, derived from human umbilical cord blood.

Illustration of an European Union long shadow flag with a weight scale
Kangstem set to begin European clinical trials of dermatitis candidate

More from South Korea

More from Focus On Asia